VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...
VYNE Therapeutics Inc.: VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe ...
Daily5d
Johnson and Johnson Gets CDSCO Panel Nod To study Guselkumab in Psoriatic Arthritis
Guselkumab targets the p19 alpha subunit of IL-23. While IL-23 promotes normal inflammatory and immune responses, the p19 and ...
eLife3d
Multi-Omics Single-Cell Analysis Reveals Key Regulators of HIV-1 Persistence and Aberrant Host Immune Responses in Early Infection
This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...
eLife5d
Synovial macrophage diversity and activation of M-CSF signaling in post-traumatic osteoarthritis
Joint injury induces rapid and sustained diversification of resident and infiltrating synovial macrophage phenotypes, underpinning osteoarthritis-associated synovitis.
CMAJ4d
Diagnosis and management of chronic rhinosinusitis
KEY POINTS Chronic rhinosinusitis refers to symptomatic inflammation of the nose and paranasal sinuses that has been present ...
gut.bmj4d
The IL23 axis plays a key role in the pathogenesis of IBD
Over the last decade, mouse models of intestinal inflammation have provided invaluable tools to identify cytokines that drive the inflammatory response. Amongst these interleukin 12 (IL12), through ...